Revolution Medicines, Inc. (RVMD): Depreciation & Amortization
$7.78M
Year ended 2025-12-31
+25.1%
3-year compound annual growth
+24.4%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.78M | +18.6% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $6.56M | +30.1% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $5.04M | +26.9% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $3.97M | +28.8% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $3.08M | +18.1% | 2023-02-27, From 2021-01-01 |
| 2020-12-31 | $2.61M | +14.9% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $2.27M | +45.1% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $1.57M | n/a | 2021-03-02, From 2018-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | $7.78M | +18.6% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $8.58M | -3.1% |
| Amgen Inc (AMGN) | 2025-12-31 | $5.17B | -7.6% |
| Repligen Corp (RGEN) | 2025-12-31 | $78.75M | +13.0% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $1.38M | -16.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $97.36M | -11.4% |
| Biogen Inc. (BIIB) | 2025-12-31 | $779.90M | +15.8% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $699.0K | +19.1% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $1.39M | +11.5% |
Compare RVMD, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗